The first episode of multiple sclerosis (MS) often manifests as numbness, vision problems or problems with balance. Up to 85% of people in this situation, which is called clinically isolated syndrome, will in time be diagnosed with MS.
Starting medication for multiple sclerosis (MS) in people who show the beginning signs of the disease is associated with prolonging the time before the disease is definitively diagnosed, suggested a long-term study published in the online issue of Neurology
, the medical journal of the American Academy of Neurology.
‘Starting medication for multiple sclerosis (MS) in people who show the beginning signs of the disease is associated with prolonging the time before the disease is definitively diagnosed.’
The study involved people who had a first episode that was suggestive of MS and an MRI that showed signs of possible MS.
"Not much research has been done on how starting treatment this early affects the long-term course of the disease," said study author Ludwig Kappos, of University Hospital Basel in Basel, Switzerland, and a member of the American Academy of Neurology. "Our study adds to the evidence supporting treatment at the earliest sign of the disease and indicates that early treatment has a long-lasting effect on disease activity."
The study started with 468 people randomly assigned to receive either early treatment with interferon beta-1b or a placebo. After participants were diagnosed with MS or after two years, the participants on the placebo could switch to interferon beta-1b or another drug. After 11 years, researchers reevaluated the 278 people who were still participating in the study, which included 167 people in the early group and 111 people in the delayed group.
Those who received the early treatment were 33% less likely to be diagnosed with MS than those who received the delayed treatment. People in the early group also had more time before their first relapse of the disease than people in the delayed group, with 1,888 days compared to 931 days. The early group also had a lower overall yearly relapse rate of 0.21 compared to 0.26 for the delayed group, which is 19 percent lower.
There was no difference between the two groups in the tests that measure overall disability or in MRI scans measuring the amount of damage caused by the disease.
"Overall, early treatment appears to have a benefit on relapses, especially early in the disease, but limited effects on other outcome measures, including outcomes reported by patients," said Brian C. Healy, of Brigham and Women's Hospital and Massachusetts General Hospital in Boston and a member of the American Academy of Neurology, who wrote an accompanying editorial.
Limitations of the study include that participants and researchers learned after the fifth-year tests which participants received the drug and which received the placebo and that after the placebo-control phase of the study, all of the participants received treatment, so there was no untreated control group after that point.